(Q47914370)

6 February 2018

title

Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study (English)

1 reference

6 February 2018

1 reference

1 reference

Maria Kallieri

1

1 reference

6 February 2018

Andriana I Papaioannou

2

1 reference

6 February 2018

Evgenia Papathanasiou

3

1 reference

6 February 2018

Polyxeni Ntontsi

4

1 reference

6 February 2018

Spyridon Papiris

5

1 reference

6 February 2018

Stelios Loukides

6

1 reference

6 February 2018

language of work or name

English

0 references

publication date

21 April 2017

1 reference

6 February 2018

published in

Postgraduate Medicine

1 reference

6 February 2018

volume

129

1 reference

6 February 2018

issue

6

1 reference

6 February 2018

page(s)

598-604

1 reference

6 February 2018

Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy

cites work

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1321945

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1321945

The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1321945

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1321945

Improvement in quality of life with omalizumab in patients with severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1321945

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1321945

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1321945

Omalizumab is effective in the long-term control of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1321945

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1321945

Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1321945

Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1321945

Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1321945

Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1321945

Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1321945

Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1321945

Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1321945

ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1321945

Performance of a new hand-held device for exhaled nitric oxide measurement in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1321945

Portable exhaled nitric oxide measurement: Comparison with the "gold standard" technique.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1321945

An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1321945

Role of interleukin-13 in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1321945

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1321945

Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1321945

10.1080/00325481.2017.1321945

21 January 2018

Identifiers

DOI

1 reference

6 February 2018

1 reference

6 February 2018